Please check your internet connection and try again.
```markdown
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Maintenance of healing of erosive esophagitis
* Reduction of risk of NSAID-induced gastric ulcers in patients at risk
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
## Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily.
* **Reduction of risk of NSAID-induced gastric ulcers:** 20 mg orally once daily.
* **Pathological hypersecretory conditions:** 40 mg orally twice daily, may be increased to a maximum of 80 mg orally twice daily.
* **Intravenous (IV) formulations:** Available for patients unable to take oral medications. Standard dosing typically 40 mg IV once daily.
## Pediatric Dosing
Dosing varies significantly by indication and age. Consult specific pediatric guidelines.
* **GERD (erosive esophagitis):**
* 1 to 5 years: 20-40 mg orally once daily.
* 5 to 16 years: 40 mg orally once daily.
* **Pathological hypersecretory conditions:**
* 2 to 16 years: 20-40 mg orally once daily, may be increased based on gastric acid output.
## Dose Adjustments
No specific dose adjustments are typically required for hepatic or renal impairment. However, caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, flatulence, and dizziness. Long-term use may be associated with:
* Increased risk of Clostridium difficile-associated diarrhea
* Bone fractures (hip, wrist, spine)
* Vitamin B12 deficiency
* Hypomagnesemia
## Key Drug Interactions
* **Certain Antiretrovirals (e.g., nelfinavir, atazanavir):** Pantoprazole may decrease absorption and serum concentrations.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **Clopidogrel:** Pantoprazole may decrease the antiplatelet effect of clopidogrel. Separate administration times or consider alternative PPIs if co-administration is necessary.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may increase concentrations of drugs metabolized by this enzyme.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias).
* Monitor for signs and symptoms of C. difficile infection.
* Consider vitamin B12 levels with prolonged therapy.
* Monitor bone mineral density in patients at risk for osteoporosis with long-term therapy.
## Clinical Pearls
* Administer 30-60 minutes before a meal for optimal efficacy.
* Do not crush or chew delayed-release formulations.
* IV administration: Reconstitute and dilute according to manufacturer instructions.
* Long-term PPI use should be reserved for patients with appropriate indications and periodically reassessed.
***
*This information is intended for clinical use and does not replace the need to consult the most current official prescribing information or local protocols.*
```
